Working... Menu

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03923166
Recruitment Status : Recruiting
First Posted : April 22, 2019
Last Update Posted : April 22, 2019
Information provided by (Responsible Party):
Li Qiao, Chinese Academy of Medical Sciences

Brief Summary:
Overexpression of the HER2 gene accounts for 20% to 30% of breast cancer. Although trastuzumab combined with chemotherapy has become the basic treatment for patients with HER2-positive advanced breast cancer, For patients who have progressed or relapsed after trastuzumab treatment, There are still many issues to explore on the choice of program of retargeted therapy. In HER2-positive advanced breast cancer, the results of Phase I and Phase I/II trials of pyrotinib or pyrotinib combined with capecitabine show that the anti-tumor effect is rapid, efficient and sustainable, and the patient is safe and well tolerated. Capecitabine is an oral cytotoxic drug that has high selectivity and specificity against tumors. Many patients need to adjust the dose due to adverse reactions, especially for patients after multi-line treatment. Previous studies have shown that sustained low-dose capecitabine reduces the adverse effects of the drug while ensuring efficacy. Based on the above, this study is to conduct a single-center, one-arm phase II clinical trial to explore the efficacy and safety of pyrotinib and capecitabine in the treatment of HER2-positive advanced breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Pyrotinib Drug: capecitabine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 35 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer: Single Arm, Single Center, Phase II Clinical Trial.
Estimated Study Start Date : April 19, 2019
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: pyrotinib+ capecitabine Drug: Pyrotinib
400mg qd

Drug: capecitabine
capecitabine 500mg tid

Primary Outcome Measures :
  1. Objective Response Rate(ORR) [ Time Frame: 4 months ]
    Refers to the proportion of patients whose tumors have shrunk to a certain proportion and maintained for a certain period of time, including cases of CR and PR, RECIST 1.1 were used to assess objective tumor remission

Secondary Outcome Measures :
  1. Progression Free Survival(PFS) [ Time Frame: 4 months ]
    the date from the first dose to the first occurrence of disease progression or death from any cause, whichever occurs first

Other Outcome Measures:
  1. disease control rate(DCR) [ Time Frame: 4 months ]
    Percentage of confirmed complete remission (CR), partial remission (PR), and disease stable (SD) cases in patients with evaluable efficacy

  2. Incidence of adverse events [ Time Frame: 1 Month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age:18~75 years;
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  3. A life expectancy of more than 12 weeks;
  4. patients have at least one measurable lesion exists according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria and progresses after the last anti-tumor treatment or during treatment;
  5. Pathologically confirmed HER2-expressing patients with locally advanced or metastatic breast cancer: HER2 IHC 3+, or HER2 IHC 2+ and FISH detection gene amplification
  6. Progression after treatment with trastuzumab (receiving at least 6 weeks of trastuzumab treatment);
  7. Have not received capecitabine for the past, or Previously received capecitabine and PFS for more than 6 months;
  8. echocardiography indicates that LVEF ≥ 50%;
  9. The laboratory tests confirmed that the bone marrow function and liver and kidney function of the patient met the following requirements before the first dose:

    1. ANC≥1.5×10^9/L;
    2. PLT≥100×10^9/L;
    3. Hb≥100 g/L
    4. serum creatinine(Scr) less than 1.5 times the upper limit of normal value or the creatinine clearance rate calculated greater than 60 mL/min;
    5. total bilirubin less than 1.5 times the upper limit of normal value
    6. aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases;
    7. urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g;
  10. Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods during the trial;
  11. The patient volunteered to join the study and signed an informed consent form.

Exclusion Criteria:

  1. Patients who have been treated with capecitabine for a period of 6 months and whose disease progresses;
  2. Previously treated with pyrotinib or neratinib;
  3. Patients with high blood pressure who are not well controlled by antihypertensive medication (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); have uncontrolled or severe cardiovascular disease, such as within 6 months before screening Refractory angina pectoris, congestive heart failure occurred; myocardial infarction occurred within 12 months before screening; any clinically significant ventricular arrhythmia history, QT interval prolongation; history of cerebrovascular accident, symptomatic and need Medically treated coronary heart disease;
  4. having significant clinical dysfunction of the digestive tract may affect the intake, transport or absorption of oral medications (eg, inability to swallow, chronic diarrhea, intestinal obstruction, etc.)
  5. Refractory, 2 degrees and above persistent diarrhea;
  6. exiting unstable brain metastasis and / or meningeal metastasis;
  7. Have undergone major surgery or severe traumatic injury, fracture, or healed wound within 4 weeks;
  8. Allergic to pyrotinib, capecitabine and/or its excipients has been confirmed;
  9. Female patients during pregnancy or lactation, female patients with fertility and positive pregnancy test, or women of childbearing age who are unwilling to take effective contraceptive measures during the whole trial period;
  10. The patient has a severe concomitant disease, or any other condition that the investigator believes is not suitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03923166

Layout table for location contacts
Contact: Binghe Xu 8687788826 ext 8687788826
Contact: Qiao Li 8687788120 ext 8687788120

Layout table for location information
China, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Beijing, Beijing, China, 100021
Contact: Qiao Li    8687788120 ext 8687788120   
Sponsors and Collaborators
Chinese Academy of Medical Sciences
Layout table for investigator information
Principal Investigator: Qiao Li Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator: Binghe Xu Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Layout table for additonal information
Responsible Party: Li Qiao, Clinical Professor, Chinese Academy of Medical Sciences Identifier: NCT03923166     History of Changes
Other Study ID Numbers: LQ006
First Posted: April 22, 2019    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents